These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14722202)

  • 61. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis.
    Wakabayashi H; Sudo A; Hasegawa M; Oka H; Uchida A; Nishioka K
    Clin Rheumatol; 2010 Jun; 29(6):671-5. PubMed ID: 20204668
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Infliximab in the treatment of rheumatoid arthritis].
    Akahoshi T; Watabe H
    Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
    Stern R; Wolfe F
    J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dose intensification with infliximab in patients with rheumatoid arthritis.
    Berger A; Edelsberg J; Li TT; Maclean JR; Oster G
    Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P; Crnkic M; Petersson IF; Saxne T;
    Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
    Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Watt I; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Schaardenburg D; van Krugten MV; Dijkmans BA; Huizinga TW; Lems WF; Kloppenburg M
    Osteoarthritis Cartilage; 2010 Oct; 18(10):1256-62. PubMed ID: 20691795
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.
    Nawata M; Saito K; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2008; 18(5):460-4. PubMed ID: 18535759
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network.
    Ducoulombier V; Solau E; Coquerelle P; Houvenagel E; Siame JL; Desprez X; Fauquert P; Guyot MH; Delcambre B; Flipo RM
    Joint Bone Spine; 2007 Jan; 74(1):56-9. PubMed ID: 17182267
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
    Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Allaart CF; van Zeben D; Kerstens PJ; Hazes JM; Zwinderman AH; Peeters AJ; de Jonge-Bok JM; Mallée C; de Beus WM; de Sonnaville PB; Ewals JA; Breedveld FC; Dijkmans BA
    Ann Intern Med; 2007 Mar; 146(6):406-15. PubMed ID: 17371885
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab.
    Horikoshi M; Ito S; Ishikawa M; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Goto D; Matsumoto I; Sumida T
    Mod Rheumatol; 2009; 19(3):229-34. PubMed ID: 19326186
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.
    van den Bemt BJ; den Broeder AA; Wolbink GJ; van den Maas A; Hekster YA; van Riel PL; Benraad HB; van den Hoogen FH
    Br J Clin Pharmacol; 2013 Dec; 76(6):939-45. PubMed ID: 23601129
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.
    Cohen SB; Kremer JM; Dandreo KJ; Reed GW; Magner R; Shan Y; Kafka S; DeHoratius RJ; Ellis L; Parenti D
    Clin Rheumatol; 2019 Sep; 38(9):2501-2508. PubMed ID: 31049762
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.
    Pittoni V; Bombardieri M; Spinelli FR; Scrivo R; Alessandri C; Conti F; Spadaro A; Valesini G
    Ann Rheum Dis; 2002 Aug; 61(8):723-5. PubMed ID: 12117680
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.
    Lequerré T; Gauthier-Jauneau AC; Bansard C; Derambure C; Hiron M; Vittecoq O; Daveau M; Mejjad O; Daragon A; Tron F; Le Loët X; Salier JP
    Arthritis Res Ther; 2006; 8(4):R105. PubMed ID: 16817978
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy].
    De Marco G; Gerloni V; Pontikaki I; Luriati A; Teruzzi B; Salmaso A; Valcamonica E; Gattinara M; Fantini F
    Reumatismo; 2007; 59(1):50-6. PubMed ID: 17435842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.